CytomX Therapeutics, Inc. (NASDAQ:CTMX) CFO Debanjan Ray Sells 2,500 Shares

CytomX Therapeutics, Inc. (NASDAQ:CTMX) CFO Debanjan Ray sold 2,500 shares of the business’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $20.58, for a total transaction of $51,450.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Debanjan Ray also recently made the following trade(s):

  • On Wednesday, November 1st, Debanjan Ray sold 2,500 shares of CytomX Therapeutics stock. The shares were sold at an average price of $20.00, for a total transaction of $50,000.00.
  • On Monday, October 2nd, Debanjan Ray sold 2,500 shares of CytomX Therapeutics stock. The shares were sold at an average price of $18.10, for a total transaction of $45,250.00.

CytomX Therapeutics, Inc. (NASDAQ CTMX) traded down $0.78 during midday trading on Thursday, hitting $21.66. 524,343 shares of the stock were exchanged, compared to its average volume of 281,695. CytomX Therapeutics, Inc. has a one year low of $10.40 and a one year high of $24.67.

Several hedge funds and other institutional investors have recently bought and sold shares of CTMX. Algert Global LLC grew its holdings in shares of CytomX Therapeutics by 31.8% during the 3rd quarter. Algert Global LLC now owns 45,853 shares of the biotechnology company’s stock worth $833,000 after purchasing an additional 11,050 shares during the period. Iguana Healthcare Management LLC grew its holdings in shares of CytomX Therapeutics by 16.7% during the 3rd quarter. Iguana Healthcare Management LLC now owns 70,000 shares of the biotechnology company’s stock worth $1,272,000 after purchasing an additional 10,000 shares during the period. AMP Capital Investors Ltd purchased a new stake in shares of CytomX Therapeutics during the 3rd quarter worth about $735,000. Allianz Asset Management GmbH purchased a new stake in shares of CytomX Therapeutics during the 3rd quarter worth about $995,000. Finally, Private Advisor Group LLC grew its holdings in shares of CytomX Therapeutics by 85.2% during the 3rd quarter. Private Advisor Group LLC now owns 185,187 shares of the biotechnology company’s stock worth $3,661,000 after purchasing an additional 85,187 shares during the period. 63.18% of the stock is owned by institutional investors.

Several brokerages recently weighed in on CTMX. Cowen reissued an “outperform” rating on shares of CytomX Therapeutics in a research note on Thursday, October 5th. ValuEngine downgraded shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Zacks Investment Research raised shares of CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 target price for the company in a research note on Monday, October 16th. Cantor Fitzgerald initiated coverage on shares of CytomX Therapeutics in a research note on Monday, October 23rd. They set an “overweight” rating and a $35.00 price objective for the company. Finally, BidaskClub downgraded shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $31.88.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://ledgergazette.com/2017/12/15/debanjan-ray-sells-2500-shares-of-cytomx-therapeutics-inc-ctmx-stock.html.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply